GENE THERAPY FOR HEPATITIS C INFECTION--CHRONIC INFECTIOUS DISEASE MODEL

这个项目是我们新倡议的一部分， 全面的研发计划，以满足 对未来输血服务的挑战性需求。日益 新出现和重新出现的疾病的威胁， 在基因和细胞治疗领域，以及不断变化的 生物技术极大地改变了输血服务。我们 病毒性肝炎研究和发展计划是建立在一个 传染病模型 我们研究基因治疗作为治疗方法的具体目标 人类丙型肝炎病毒（HCV）感染和发展的途径 这种方法作为慢性传染病的模型是（1） 建立造血干细胞中功能可测量基因表达 细胞，使用HCV基因的病毒介导的基因递送系统;（2） 在造血细胞中发展谱系特异性基因表达， HCV基因;（3）证明谱系特异性基因的功效 通过细胞毒性T淋巴细胞功能评估表达 针对HCV特异性表位的测定和肿瘤杀伤测定; 和（4）建立谱系特异性基因表达作为治疗 治疗慢性HCV感染的方法。

This project is part of our new initiative to develop a comprehensive research and development program to meet the challenging demands of future transfusion services. The increasing threats of emerging and re-emerging diseases, the quickened progress in the field of gene and cell therapy, and the ever-changing biotechnology have transformed the transfusion services greatly. Our viral hepatitis research and development program is built on an infectious disease model. Our specific goals for investigating gene therapy as a therapeutic approach for human hepatitis C virus (HCV) infection and developing this approach as a model for chronic infectious diseases are to (1) establish a functionally measurable gene expression in hematopoietic cells, using a viral-mediated gene delivery system for HCV gene; (2) develop lineage-specific gene expression in hematopoietic cells of HCV genes; (3) demonstrate the efficacy of lineage-specific gene expression by functional assessment with cytotoxic T lymphocyte assays and tumor killing assays directed to HCV specific epitopes; and (4) establish lineage-specific gene expression as a therapeutic modality against chronic HCV infection.